Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy

被引：135
作者：
Sun, Bingjun [1 ]
Luo, Cong [1 ]
Cui, Weiping [1 ]
Sun, Jin [1 ,2 ]
He, Zhonggui [1 ]
机构：
[1] Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, 59 Mailbox,103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China
[2] Shenyang Pharmaceut Univ, Sch Pharm, Municipal Key Lab Biopharmaceut, Shenyang 110016, Liaoning, Peoples R China
来源：
JOURNAL OF CONTROLLED RELEASE | 2017年 / 264卷
基金：
中国国家自然科学基金;
关键词：
Cancer therapy; Unsaturated fatty acids; Prodrugs; Prodrug-based nano-DDS; CONJUGATED LINOLEIC-ACID; DHA-PACLITAXEL TAXOPREXIN; CHOLESTEROL-RICH EMULSION; NUCLEOSIDE TRANSPORTER 1; LIPID VECTOR TECHNOLOGY; TARGETED DRUG-DELIVERY; PHASE-2; OPEN-LABEL; TUMOR-CELL LINES; II OPEN-LABEL; DOCOSAHEXAENOIC ACID;
D O I：
10.1016/j.jconrel.2017.08.034
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Unsaturated fatty acids (UFAs), with the distinct advantages of good biocompatibility and innate tumor-targeting effect, have been widely investigated for the rational design of chemotherapy agent-unsaturated fatty acid (CA-UFA) prodrugs in cancer therapy. Among them, several CA-UFA prodrugs have successfully entered clinical trials and are promising prospects for potential clinical applications. In addition, CA-UFA prodrug-based nanoparticulate drug delivery systems (nano-DDS), which integrate the advantages of CA-UFA prodrugs and nano-DDS, have been emerging as versatile nano-carriers for the efficient delivery of chemotherapeutics. In this paper, we review the advanced drug delivery strategies based on UFA conjugates and focus on the recent advances in CA-UFA prodrugs and the emerging CA-UFA prodrug-based nano-DDS. First, we discuss the rational design of CA-UFA prodrugs in response to the multiple obstacles in chemotherapy, with particular emphasis on the latest progress in both preclinical studies and clinical trials. Moreover, the emerging CA-UFA prodrug-based nano-DDS are also addressed. Finally, the prospects and potential challenges of CA-UFA prodrug-based drug delivery strategies in chemotherapy are highlighted.
引用
收藏
页码：145 / 159
页数：15
相关论文
共 148 条
[31]  
DiNardo CD, 2013, FUTURE ONCOL, V9, P1073, DOI [10.2217/fon.13.130, 10.2217/FON.13.130]
[32]   Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma [J].
Du, Ruo ;
Zhong, Ting ;
Zhang, Wei-Qiang ;
Song, Ping ;
Song, Wen-Ding ;
Zhao, Yang ;
Chao-Wang ;
Tang, Yi-Qun ;
Zhang, Xuan ;
Zhang, Qiang .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2014, 9 :3091-+
[33]   Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study [J].
Dueland, Svein ;
Aamdal, Steinar ;
Lind, Michael J. ;
Thomas, Hilary ;
Sandvold, Marit Liland ;
Gaullier, Jean-Michel ;
Rasch, Wenche .
ACTA ONCOLOGICA, 2009, 48 (01) :137-145
[34]  
Earl H.M., 2017, LANCET ONCOL
[35]   Modulation of doxorubicin activity in cancer cells by conjugation with fatty acyl and terpenyl hydrazones [J].
Effenberger, K. ;
Breyer, S. ;
Schobert, R. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (05) :1947-1954
[36]   Interaction of brain fatty acid-binding protein with the polyunsaturated fatty acid environment as a potential determinant of poor prognosis in malignant glioma [J].
Elsherbiny, Marwa E. ;
Emara, Marwan ;
Godbout, Roseline .
PROGRESS IN LIPID RESEARCH, 2013, 52 (04) :562-570
[37]   Nanoparticles as delivery carriers for anticancer prodrugs [J].
Fang, Jia-You ;
Al-Suwayeh, Saleh A. .
EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (06) :657-669
[38]   Therapeutic strategies by modulating oxygen stress in cancer and inflammation [J].
Fang, Jun ;
Seki, Takahiro ;
Maeda, Hiroshi .
ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (04) :290-302
[39]   Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors [J].
Fang, Tao ;
Dong, Yuehan ;
Zhang, Xiaomin ;
Xie, Ke ;
Lin, Li ;
Wang, Hangxiang .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 512 (01) :39-48
[40]   Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, TaxoprexinA®, in resistant solid tumor malignancies [J].
Fracasso, Paula M. ;
Picus, Joel ;
Wildi, Jonathan D. ;
Goodner, Sherry A. ;
Creekmore, Allison N. ;
Gao, Feng ;
Govindan, Ramaswamy ;
Ellis, Matthew J. ;
Tan, Benjamin R. ;
Linette, Gerald P. ;
Fu, ChauHwei J. ;
Pentikis, Helen S. ;
Zumbrun, Stephen C. ;
Egorin, Merrill J. ;
Bellet, Robert E. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) :451-458
12345678910